Towards Healthcare
Generative AI in Drug Discovery Market 2025 Surges USD 318.55 Bn with 27.42% C...

Generative AI in Drug Discovery Market Cloud-Based Deployments Dominate with 71% Share

Projections indicate that, the global generative AI in drug discovery market will increase from USD 250 million in 2024 to USD 2847.43 million by 2034, experiencing a CAGR of 27.42% over the next 10 years. The generative AI in drug discovery market is growing rapidly due to technological advancements and rising government initiatives to develop novel drugs. North America is the dominant region due to the strong presence of pharmaceutical companies.

Content

  • Insight Code: 5816
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The generative AI in drug discovery market is projected to reach USD 2847.43 million by 2034, growing at a CAGR of 27.42% from 2024 to 2034.

North America is currently leading the generative AI in drug discovery market due to rising cancer patients, growing clinical trials, and rising government support.

The generative AI in drug discovery market includes six segments such as by application, by therapeutic area, by technology, by deployment mode, by end-user, and by region.

Some key players include Insilico Medicine, Exscientia, Atomwise, BenevolentAI, Absci, etc. 

Key trends include growing research in genomics & personalized medicine, FDA approvals for novel drugs, and a rising population.

By creating enormous libraries of virtual substances and forecasting their characteristics, generative AI systems accelerate the laborious traditional drug development process. This enables researchers to focus on the most promising ideas.

By quickly generating new drug candidates, forecasting their characteristics, and streamlining the drug design process, generative AI chatbots significantly accelerate drug research.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions